Subscribe
artco-shutterstock-com
Artco / Shutterstock.com
27 September 2016Americas

Glenmark partners with Particle Sciences in Abraxane generic deal

India-based pharmaceutical company Glenmark has signed a wide-ranging drug agreement with Particle Sciences, a provider of drug development services.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Celgene reaches settlement with Actavis
31 January 2018   Biopharmaceutical company Celgene has reached an agreement with Actavis that will terminate pending patent litigation over Abraxane.


Editor's picks

Astellas win strengthens blockbuster drug's European position
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

Editor's picks

Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025
Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

More on this story

Americas
Celgene reaches settlement with Actavis
31 January 2018   Biopharmaceutical company Celgene has reached an agreement with Actavis that will terminate pending patent litigation over Abraxane.

More on this story

Americas
Celgene reaches settlement with Actavis
31 January 2018   Biopharmaceutical company Celgene has reached an agreement with Actavis that will terminate pending patent litigation over Abraxane.

More features

The rise of pro-NPE and patent sentiment in the US
UPC sees rising small molecule litigation with Pfizer in the hot seat
Why the Caribbean cannabis economy is ripe for IP protection
China filings push rise in patent applications in Ireland
Brain disorder medtech rivals butt heads at ITC
The right formula: Minimising the cost of chemical and pharma patents
‘This is not a rescue deal’: How an acquisition fits London firm's plan
Alston & Bird partner with strong Japanese ties jumps to new firm